Behcets Syndrome - A Pipeline Analysis Report

Overview of the drug development pipeline for Behcet’s syndrome

Behcet’s syndrome or Behcet’s disease is a rare type of autoimmune disorder that results in the inflammation of blood vessels throughout the body. It affects multiple body parts. The complications caused due to the Behcet’s syndrome depends on the site of the body parts and symptoms. For instance, untreated uveitis, the inflammation of the middle layer of the eye between retina and sclera, can result in the decreasing of vision or even blindness. The syndrome tends to develop more in young adults who are in their 20s and 30s of all genders and races. It is prevalent significantly in Turkey. In the Middle Eastern countries, males tend to get more affected than females. However, in the US, Japan, South Korea, and other Western countries, it occurs more in females. The prevalence of Behcet’s syndrome is increasing throughout the world due to better disease recognition and reporting of cases. Consequently, the increasing incidences of the disease are expected to promote the drug development for Behcet’s syndrome over the next few years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for Behcet’s syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Behcet’s syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Bristol-Myers Squibb
• Celgene
• Jansen Korea
• Novartis

Therapeutic assessment of the drug development pipeline for Behcet’s syndrome by route of administration

• Parenteral
• Oral
• Subcutaneous

The parenteral route of administration (ROA) involves injecting the drug directly into the body, bypassing the skin and mucous membranes, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for Behcet’s syndrome for AMD by therapy

• Monotherapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for Behcet’s syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for Behcet’s syndrome?
• What are the companies that are currently involved in the development of drug molecules for Behcet’s syndrome?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.